STM: Researchers have found a potentially promising combination of treatments for renal cell carcinoma

January 22, 2021 /--- (RCC) is the most common form of kidney cancer.
2018, there are an estimated 403,000 new RCC cases and 175,000 deaths from kidney cancer worldwide.
currently, the five-year survival rate for metastasis RCC patients is only about 12%.
current treatments include inhibitors for veGF and PD-1 pathways.
, however, most patients become resistant to treatment and still need new combined theraps to enhance the effectiveness of these current methods.
(Photo Source: Www.pixabay.com) Now, researchers have shown that ACE2 expression is a good prognostic factor for RCC, that defects in ACE2 mediate cancer cell resistance to classic therapies, and that in preclinical models, drug therapy downstream of ACE2 can improve tumor response in RCC and significantly prolong survival.
team, led by Dr Rupal Bhatt of bidMC and Dr Thomas Walther of the University of Cork in Ireland, published their findings in the journal Science Translational Medicine.
" our team reported that ACE2 is a new protective molecule in RCC, and based on this finding, we have demonstrated angiosin-(1-7), a small peptide produced by ACE2 that can be used to control tumor growth in preclinical models.
"Our findings suggest that angiosin-(1-7) can be developed in clinical trials as a promising treatment option for RCC patients combined with current standard treatments and has strong potential to improve overall survival," said Bhatt, a medical oncologist at BIDMC and an associate professor of medicine at Harvard Medical School.
"ACE2 is an enzyme that belongs to the nephrine-angiosin system (RAS) and antagonists the classic angiosin II/AT1 ligand pathway.
interestingly, it is also a subject of SARS-CoV2 protrusion protein, which is reduced by the virus to lead to the fatality of acute respiratory distress syndrome in patients with COVID-19.
Bhatt, Walther and colleagues showed that higher ACE2 expression in RCC patients was associated with better overall survival.
also demonstrated that VEGF inhibitors such as schonithinib and acetinib can reduce ACE2 expression in cultured tumor cells and tumors in RCC mouse models.
authors also showed that hemangiotrophy-(1-7) triple therapy for VEGF pathway inhibitors and anti-PD-L1 was superior to actual standard therapies inhibited by VEGR and PD-1 pathways.
"Our study shows that angiosin (1-7) can provide promising treatment options for RCC patients who use RCC in combination with VEGF pathway inhibitors, and that resistance to VEGF pathway inhibitors is a common problem in cancer treatment, so our findings have broader implications for VEGF pathway inhibitor therapy, where diseases other than RCC can be extended to other types of cancer.
" (Bioon.com) Source: Researchers guangmingly forwarding for the original source of the renal cell carcinoma Source: P. Khanna el al., "ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma," Science Translational Medicine (2021). stm.sciencemag.org/lookup/doi/ ... scitranslmed.abc0170